Terms: = Germ cell tumor AND KIT, C-Kit, 3815, ENSG00000157404, CD117, SCFR, P10721 AND Treatment
819 results:
1. Detection of In Vivo-like cells by a Biosensor Chip Based on Metamaterials in Terahertz Regime.
Han L; Wang Y; Chen K; Gao H; Xia K; Ge Q; Yang J; Shi W; Ruan C
Biosensors (Basel); 2024 May; 14(5):. PubMed ID: 38785704
[TBL] [Abstract] [Full Text] [Related]
2. Knockdown of trem2 promotes proinflammatory microglia and inhibits glioma progression via the JAK2/STAT3 and NF-κB pathways.
Yan Y; Bai S; Han H; Dai J; Niu L; Wang H; Dong Q; Yin H; Yuan G; Pan Y
Cell Commun Signal; 2024 May; 22(1):272. PubMed ID: 38750472
[TBL] [Abstract] [Full Text] [Related]
3. Glycyrrhizic acid inhibits DNA damage repair and enhances cisplatin-induced apoptosis of melanoma cells.
Bian F; Niu FH; Qu PY; Gong F; Yan JZ
Chem Biol Drug Des; 2024 May; 103(5):e14536. PubMed ID: 38725079
[TBL] [Abstract] [Full Text] [Related]
4. NRN1 interacts with Notch to increase oncogenic STAT3 signaling in melanoma.
Devitt L; Westphal D; Pieger K; Schneider N; Bosserhoff AK; Kuphal S
Cell Commun Signal; 2024 May; 22(1):256. PubMed ID: 38705997
[TBL] [Abstract] [Full Text] [Related]
5. EP300 through upregulating the expression of vimentin to promote the progression of chordoma.
Wen L; Xie B; Li H; Huang J; Shi Y; Tao Y; Chen Y
Neurosurg Focus; 2024 May; 56(5):E17. PubMed ID: 38691868
[TBL] [Abstract] [Full Text] [Related]
6. Autophagy-related CMTM6 promotes glioblastoma progression by activating Wnt/β-catenin pathway and acts as an onco-immunological biomarker.
Dai L; Xiao J; Li X; Tao Y; Zhou P; Lyu L; Shi Z; Liang X; Jia Z; Jiang S
J Gene Med; 2024 May; 26(5):e3685. PubMed ID: 38686653
[TBL] [Abstract] [Full Text] [Related]
7. PUMC-MB1 is a novel group 3 medulloblastoma preclinical model, sensitive to PI3K/mTOR dual inhibitor.
Wang S; Zhang D; Wang J; Peng X; Sun H; Ji Y; Yang Z; Bian X; Hou Y; Ge M; Liu Y
J Neurooncol; 2024 May; 168(1):139-149. PubMed ID: 38662151
[TBL] [Abstract] [Full Text] [Related]
8. Regorafenib and glioblastoma: a literature review of preclinical studies, molecular mechanisms and clinical effectiveness.
Mongiardi MP; Pallini R; D'Alessandris QG; Levi A; Falchetti ML
Expert Rev Mol Med; 2024 Apr; 26():e5. PubMed ID: 38563164
[TBL] [Abstract] [Full Text] [Related]
9. IL-12-Overexpressed Nanoparticles Suppress the Proliferation of Melanoma Through Inducing ICD and Activating DC, CD8
Shen HH; Peng JF; Wang RR; Wang PY; Zhang JX; Sun HF; Liang Y; Li YM; Xue JN; Li YJ; Sun GB; Xie SY
Int J Nanomedicine; 2024; 19():2755-2772. PubMed ID: 38525008
[TBL] [Abstract] [Full Text] [Related]
10. Molecular Frontiers in Melanoma: Pathogenesis, Diagnosis, and Therapeutic Advances.
Kim HJ; Kim YH
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474231
[TBL] [Abstract] [Full Text] [Related]
11. Nilotinib in kit-driven advanced melanoma: Results from the phase II single-arm NICAM trial.
Larkin J; Marais R; Porta N; Gonzalez de Castro D; Parsons L; Messiou C; Stamp G; Thompson L; Edmonds K; Sarker S; Banerji J; Lorigan P; Evans TRJ; Corrie P; Marshall E; Middleton MR; Nathan P; Nicholson S; Ottensmeier C; Plummer R; Bliss J; Valpione S; Turajlic S
Cell Rep Med; 2024 Mar; 5(3):101435. PubMed ID: 38417447
[TBL] [Abstract] [Full Text] [Related]
12. Genistin Represses the Proliferation and Angiogenesis While Accelerating the Apoptosis of Glioma cells by Modulating the FOXC1-Mediated Wnt Signaling Pathway.
Lan X; Gui Z; Chen T; Tang M; Wang H
Discov Med; 2024 Feb; 36(181):332-342. PubMed ID: 38409838
[TBL] [Abstract] [Full Text] [Related]
13. FTO promotes the progression of retinoblastoma through YTHDF2-dependent N6-methyladenosine modification in E2F3.
Xie W; Shao Y; Bo Q; Li Z; Yu Q; Wang L; Wu G
Mol Carcinog; 2024 May; 63(5):926-937. PubMed ID: 38380957
[TBL] [Abstract] [Full Text] [Related]
14. Mechanistic study of the anti-excitatory amino acid toxicity of Bushen Zhichan decoction for Parkinson's disease based on the transcriptional regulation of EAAT1 by YY1.
Liu L; Tian X; Li W
J Ethnopharmacol; 2024 May; 325():117857. PubMed ID: 38350506
[TBL] [Abstract] [Full Text] [Related]
15. Exploration of genetic characterization in hyperprogressive disease after immunotherapy retreatment in a patient with LCNEC: A case report.
Zhang Y; Yang J; Shao T; Chen J; Shu Q; Shou L
Hum Vaccin Immunother; 2024 Dec; 20(1):2313281. PubMed ID: 38348622
[TBL] [Abstract] [Full Text] [Related]
16. FOXM1 promote the growth and metastasis of uveal melanoma cells by regulating CDK2 expression.
Bai X; Li S; Luo Y
Int Ophthalmol; 2024 Feb; 44(1):55. PubMed ID: 38342795
[TBL] [Abstract] [Full Text] [Related]
17. Evodiamine inhibits growth of vemurafenib drug-resistant melanoma via suppressing IRS4/PI3K/AKT signaling pathway.
Guo X; Huang S; Zhang Y; Wang H; Li L; Ran J; Chen D; Li X; Li J
J Nat Med; 2024 Mar; 78(2):342-354. PubMed ID: 38324123
[TBL] [Abstract] [Full Text] [Related]
18. Etomidate inhibits tumor growth of glioblastoma by regulating M1 macrophage polarization.
Gao C; Nie Y
Metab Brain Dis; 2024 Apr; 39(4):569-576. PubMed ID: 38300392
[TBL] [Abstract] [Full Text] [Related]
19. The promotive role of lncRNA MIR205HG in proliferation, invasion, and migration of melanoma cells via the JMJD2C/ALKBH5 axis.
Liu Y; Wang S; Wei S; Qiu X; Mei Y; Yan L
PLoS One; 2024; 19(1):e0290986. PubMed ID: 38252669
[TBL] [Abstract] [Full Text] [Related]
20. Anlotinib alone or in combination with bevacizumab in the treatment of recurrent high-grade glioma: a prospective single-arm, open-label phase II trial.
Zhao S; Zhang M; Zhang Q; Wu J; Dai H
BMC Cancer; 2024 Jan; 24(1):6. PubMed ID: 38166698
[TBL] [Abstract] [Full Text] [Related]
[Next]
